This finding raises the intriguing question of whether neratinib potentially reverses resistance to CDK4/6 inhibitors combined with endocrine therapy, because of low HER2 expression in HR+/HER2-low breast cancer. This evidence concerns the gene CDK4 and breast carcinoma.